Novo Nordisk keeps pushing the boundaries of obesity innovation by revealing the whole Phase 3 REDEFINE 1 and 2 trial data, which shed light on CagriSema’s revolutionary potential.
Clinical Trials
Gilead has paused dosing in its Phase 1b studies of GS-1720 and GS-4182—two promising long-acting HIV-1 therapies after identifying tolerability issues. No serious adverse events were reported, and the company is evaluating future development pathways.
Sanofi unveiled promising new data at ISTH 2025, spotlighting rilzabrutinib’s potential in immune thrombocytopenia and reinforcing its leadership in hemophilia care through advancements with ALTUVIIIO and QDENGA.
Roche’s Evrysdi® 5mg tablet for spinal muscular atrophy receives European Commission approval, offering a convenient, room-temperature stable treatment option for patients aged 2 and above.
Johnson & Johnson reports a 95% four-year progression-free survival rate using the DARZALEX FASPRO®-based regimen in transplant-eligible, newly diagnosed multiple myeloma patients who achieved sustained MRD negativity.
Amgen has revealed ground-breaking findings from its Phase 3 DeLLphi-304 clinical trial, showing that Imdelltra® (tarlatamab-dlle) dramatically decreased the risk of death in patients with extensive-stage small cell lung cancer (ES-SCLC) by 40% when compared to standard chemotherapy. Patients whose illness had worsened after receiving platinum-based chemotherapy were included in […]
Roche’s Itovebi™ (inavolisib) significantly improved overall survival in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer patients, according to final Phase III INAVO120 trial results.
Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.
Johnson & Johnson MedTech’s MONARCH™ Platform demonstrated 98.7% navigation success and 83.2% diagnostic yield in the TARGET study, confirming its safety and efficacy for robotically assisted bronchoscopy.
GSK has halted its Phase III PIVOT-PO trial early after an independent review confirmed tebipenem HBr met its primary efficacy goal in treating complicated urinary tract infections, marking a major step forward for oral antibiotic options.
